Find Clinical Trial

Home » Find Clinical Trials » A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation

← Back

Study Phase	Phase 3

Therapeutic Area	Cancers

Indication	Glioma

Sponsor	Institut de Recherches Internationales Servier

Active substance/ Medical device	vorasidenib

Active Substance Code	AG881

Protocol Code	AG881-C-004

EudraCT Code	2019‐002481‐13

NCT Code	NCT04164901

Other Protocol Name :	INDIGO

Documents and links

Lay summary

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.